KR20240117521A - 세로토닌 재흡수 억제제 금단 증후군의 치료 - Google Patents

세로토닌 재흡수 억제제 금단 증후군의 치료 Download PDF

Info

Publication number
KR20240117521A
KR20240117521A KR1020247003929A KR20247003929A KR20240117521A KR 20240117521 A KR20240117521 A KR 20240117521A KR 1020247003929 A KR1020247003929 A KR 1020247003929A KR 20247003929 A KR20247003929 A KR 20247003929A KR 20240117521 A KR20240117521 A KR 20240117521A
Authority
KR
South Korea
Prior art keywords
escitalopram
gentisate
days
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247003929A
Other languages
English (en)
Korean (ko)
Inventor
마크 하슬레톤
Original Assignee
마크 하슬레톤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마크 하슬레톤 filed Critical 마크 하슬레톤
Publication of KR20240117521A publication Critical patent/KR20240117521A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
KR1020247003929A 2021-07-06 2022-07-06 세로토닌 재흡수 억제제 금단 증후군의 치료 Pending KR20240117521A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163218535P 2021-07-06 2021-07-06
US63/218,535 2021-07-06
PCT/IB2022/056229 WO2023281406A1 (en) 2021-07-06 2022-07-06 Treatment of serotonin reuptake inhibitor withdrawal syndrome

Publications (1)

Publication Number Publication Date
KR20240117521A true KR20240117521A (ko) 2024-08-01

Family

ID=82942712

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247003929A Pending KR20240117521A (ko) 2021-07-06 2022-07-06 세로토닌 재흡수 억제제 금단 증후군의 치료

Country Status (8)

Country Link
US (1) US20240277654A1 (https=)
EP (1) EP4366726A1 (https=)
JP (1) JP2024529009A (https=)
KR (1) KR20240117521A (https=)
CN (1) CN118284414A (https=)
AU (1) AU2022308198A1 (https=)
CA (1) CA3227324A1 (https=)
WO (1) WO2023281406A1 (https=)

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DK1635875T3 (da) 2003-06-26 2009-01-12 Psivida Inc In-situ-geldannende lægemiddeladministrationssystem
CA2553254C (en) 2004-01-12 2013-12-17 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
NL1026261C2 (nl) 2004-05-25 2005-11-28 Nanomi B V Sproei inrichting met een nozzleplaat voorzien van structuren ter bevordering van self-breakup, een nozzleplaat, alsmede werkwijzen ter vervaardiging en toepassing van een dergelijke nozzleplaat.
US8236292B2 (en) 2004-06-04 2012-08-07 Camurus Ab Liquid depot formulations
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2007139744A2 (en) 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
US8206735B2 (en) 2006-07-11 2012-06-26 Foresee Pharmaceuticals, Llc Pharmaceutical compositions for sustained release delivery of peptides
FI20070174A0 (fi) 2007-02-28 2007-02-28 Delsitech Oy Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
ES2324009B1 (es) 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
WO2009148580A2 (en) 2008-06-03 2009-12-10 Qlt Usa, Inc. Controlled release copolymer formulation with improved release kinetics
RU2504360C2 (ru) 2008-08-12 2014-01-20 Новартис Аг Фармацевтические композиции
PT2355853T (pt) 2008-10-10 2017-03-15 Polyactiva Pty Ltd Conjugados polímero biodegradável ¿ unidade bioativa
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
CA2792484C (en) 2009-03-12 2017-10-31 Delpor, Inc. Implantable device for long-term delivery of drugs
AU2016228315B2 (en) * 2009-09-17 2018-01-04 Bespoke Bioscience, Llc Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
HUE060304T2 (hu) 2010-01-04 2023-02-28 Mapi Pharma Ltd Glatiramer acetátot tartalmazó depó rendszer
EP2343046A1 (en) 2010-01-08 2011-07-13 Nirvana's Tree House B.V. Functionalised triblock copolymers and compositions containing such polymers
PL2394663T3 (pl) 2010-05-31 2022-02-21 Laboratorios Farmaceuticos Rovi, S.A. Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
FR2968994B1 (fr) 2010-12-17 2012-12-28 Flamel Tech Sa Procede de preparation de nanoparticules
US9023897B2 (en) 2010-12-29 2015-05-05 Medincell Biodegradable drug delivery compositions
HRP20192276T1 (hr) 2011-06-10 2020-05-15 Ramscor, Inc. Formulacije s produljenim oslobađanjem za dostavu proteina u oko i postupci njihove pripreme
US20130144250A1 (en) 2011-10-24 2013-06-06 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions and methods of treatment thereof
BR112014017969A8 (pt) 2012-01-23 2017-07-11 Allergan Inc Microesferas ou micropartículas bioerodíveis ou bio-degradáveis liberadas por tempo suspensas em uma formulação de droga injetável de formação de depósito
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
US9943484B2 (en) 2013-06-20 2018-04-17 Pharmathen S.A. Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile
CN111194312A (zh) * 2017-10-09 2020-05-22 提瓦制药工业公司 依地普仑的新盐和固态形式

Also Published As

Publication number Publication date
US20240277654A1 (en) 2024-08-22
WO2023281406A1 (en) 2023-01-12
JP2024529009A (ja) 2024-08-01
CN118284414A (zh) 2024-07-02
EP4366726A1 (en) 2024-05-15
AU2022308198A1 (en) 2024-02-01
CA3227324A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
US12496300B2 (en) Methods of treating acute depression and anxiety
AU2019203448B2 (en) Fenfluramine for use in the treatment of dravet syndrome
EP3064206B1 (en) Treatment of huntington's disease using laquinimod
EP1001760B1 (en) Composition for controlling mood disorders in healthy individuals
JP2003506483A (ja) シクロベンザプリンおよびその組成物による全般性不安障害の処置
EP4218767A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
EP3655036B1 (en) Compositions for treating stress-related disorders
Weinbroum et al. The use of flumazenil in the management of acute drug poisoning—a review
TW200822927A (en) Method of treating movement disorders using barbituric acid derivatives
SK287396B6 (sk) Použitie mirtazapínu na liečenie porúch spánku
KR20240117521A (ko) 세로토닌 재흡수 억제제 금단 증후군의 치료
WO2024102802A1 (en) Zelatriazin for the treatment of depression
TWI864376B (zh) 焦慮症處置用組成物及處置方法
KR101978459B1 (ko) 조루증 치료용 약학 조성물 및 조루증 치료 방법
EP3130339B1 (en) A compound for use in the treatment of comorbid anxiety disorder and depression disorder
US20110065749A1 (en) Method and pharmaceutical composition for treatment of mental disorders
US20240100012A1 (en) Pharmaceutical dosage form
HK40096830A (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
Best apnea/hypopnea syndrome (OSAHS)
TW200800160A (en) Prophylactic or therapeutic agent for sleep disorder

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000